A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

NCT07392320 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

142

Enrollment

OTHER

Sponsor class

Conditions

Nasopharangeal Cancer

Interventions

DRUG: TP+PD1+CCRT
DRUG: PD-1 Monoclonal Antibody
DRUG: Capecitabine

Sponsor

Sun Yat-sen University